SavedAdd your journal

Journals / Journal of Basic and Clinical Health Sciences / 2020 / Volume: 4 Issue: 3

Serum Fetuin A and Secreted Phosphoprotein 24 as Diagnostic Markers in Inflammatory Bowel Disease

Inanc Karakoyun(University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Biochemistry, Izmir, Turkey)
Ferruh Kemal Isman(Istanbul Medeniyet University, Goztepe Training and Research Hospital, Department of Medical Biochemistry, Istanbul, Turkey)
Banu Isbilen Basok(University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Biochemistry, Izmir, Turkey)
Fatma Demet Arslan(University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Biochemistry, Izmir, Turkey)
Bulent Calik(University of Health Sciences, Tepecik Training and Research Hospital, Department of General Surgery, Izmir, Turkey)
Nevin Genc Kahraman(Istanbul Medeniyet University, Goztepe Training and Research Hospital, Department of Medical Biochemistry, Istanbul, Turkey)
Gokhan Akbulut(University of Health Sciences, Tepecik Training and Research Hospital, Department of General Surgery, Izmir, Turkey)
Celal Ulasoglu(Istanbul Medeniyet University, Goztepe Training and Research Hospital, Department of Gastroenterology, Istanbul, Turkey)
Pages
—
Publication Date
2020-09-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Median fetuin A levels were significantly lower in the UC 249 mg/L and CD 254 mg/L groups compared to HC 352 mg/L UC vs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: A completely satisfactory biomarker has yet to be identified for the diagnosis and characterization of inflammatory bowel disease IBD .
📊
Key Findings & Data:This study evaluated the utility of fetuin A and secreted phosphoprotein 24 kDa Spp24 as novel biomarkers in IBD.
💡
Conclusion & Impact:Median fetuin A levels were significantly lower in the UC 249 mg/L and CD 254 mg/L groups compared to HC 352 mg/L UC vs.
🔬Design:Article
📍Scope:Comprehensive Sample
⚙️Variables:Fetuin A · inflammatory bowel disease · secreted phosphoprotein 24

Abstract

Purpose: A completely satisfactory biomarker has yet to be identified for the diagnosis and characterization of inflammatory bowel disease IBD . This study evaluated the utility of fetuin A and secreted phosphoprotein 24 kDa Spp24 as novel biomarkers in IBD. Methods: Ninety IBD patients, 54 with ulcerative colitis UC and 36 with Crohn’s disease CD , and 41 healthy controls HC were included. Serum fetuin A, Spp24, TNF-α, and IFN-γ levels were analyzed by ELISA. Serum C-reactive protein CRP levels were determined turbidimetrically by an automated procedure. Results: There were no significant differences in serum Spp24 levels among the UC 17.15 pg/mL, mean , CD 18.88 pg/mL , and HC 14.77 pg/mL groups P>0.05 . Median fetuin A levels were significantly lower in the UC 249 mg/L and CD 254 mg/L groups compared to HC 352 mg/L UC vs. HC P

🔖

Cite This Article

Karakoyun, I., Isman, F. K., Basok, B. I., Arslan, F. D., Calik, B., Kahraman, N. G., Akbulut, G., Ulasoglu, C. (2020). Serum Fetuin A and Secreted Phosphoprotein 24 as Diagnostic Markers in Inflammatory Bowel Disease. Journal of Basic and Clinical Health Sciences, Volume: 4 Issue: 3. https://doi.org/10.30621/jbachs.2020.1123

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (29)

  1. de Souza HSP, Fiocchi C. Immunopathogenesis of IBD. current state of the art. Nat Rev Gastroenterol Hepatol 2016;13:13–27. [CrossRef]
  2. Hagel AF, de Rossi T, Konturek PC, et al. Plasma histamine and tumour necrosis factor-alpha levels in crohn’s disease and ulcerative colitis at various stages of disease. J Physiol Pharmacol 2015;66:549–556. http:// www.jpp.krakow.pl/journal/archive/08_15/pdf/549_08_15_article.pdf
  3. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res 2012;159:313–325. [CrossRef]
  4. Wasinger VC, Yau Y, Duo X, et al. Low mass blood peptides discriminative of inflammatory bowel disease (IBD) severity: A quantitative proteomic perspective. Mol Cell Proteomics 2016;15:256–265. [CrossRef]
  5. Liu Y, Chen X, Xu Q, et al. SPP2 mutations cause autosomal dominant retinitis pigmentosa. Sci Rep 2015;5:14867. [CrossRef]
  6. Gurbuz C, Polat H, Yildirim A, Canat L, Bayram G, Çaskurlu T. The role of alpha2-heremans schmid glycoprotein (Fetuin-A) in the etiology of urolithiasis. Curr Urol 2010;4:10–14. [CrossRef]
  7. Ombrellino M, Wang H, Yang H, et al. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock 2001;15:181–185. [CrossRef]
  8. Bonyadi M, Abdolmohammadi R, Jahanafrooz Z, Somy MH, Khoshbaten M. TNF-alpha gene polymorphisms in Iranian Azari Turkish patients with inflammatory bowel diseases. Saudi J Gastroenterol 2014;20:108–112. [CrossRef]
  9. Műzes G, Molnár B, Tulassay Z, Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol 2012;18:5848–5861. [CrossRef]
  10. Manolakis AC, Christodoulidis G, Kapsoritakis AN, et al. α2- Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease. World J Gastroenterol 2017;23:437–446. [CrossRef]
  11. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a crohn’s disease activity index. National cooperative crohn’s disease study. Gastroenterology 1976;70:439–444. [CrossRef]
  12. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with crohn’s disease. Gastroenterology 2002;122:512–530. [CrossRef]
  13. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of crohn’s disease: report of the working party for the world congresses of gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8–15. [CrossRef]
  14. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19:5A–36A. [CrossRef]
  15. Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol 2015;21:11246–11259. [CrossRef]
  16. Hosmer DW, Lemeshow SL. Applied Logistic Regression, 2nd ed. Wiley: New York; 2000. http://resource.heartonline. cn/20150528/1_3kOQSTg.pdf
  17. Van Assche G, Dignass A, Panes J, et al; European Crohn’s and Colitis Organization (ECCO). The second European evidencebased consensus on the diagnosis and management of crohn’s disease: Definitions and diagnosis. J Crohns Colitis 2010;4:7–27. [CrossRef]
  18. Dignass A, Eliakim R, Magro F, et al. Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965– 990. [CrossRef]
  19. Pepys MB and Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003;111:1805–1812. [CrossRef]
  20. S Vermeire, G Van Assche, P Rutgeerts. Laboratory markers in IBD. useful, magic, or unnecessary toys? Gut 2006;55:426–431. [CrossRef]
  21. Lewis JD. C-reactive protein: anti-placebo or predictor of response. Gastroenterology 2005;129:1114–1116. [CrossRef]
  22. Hu B, Coulson L, Moyer B, Price PA. Isolation and molecular cloning of a novel bone phosphoprotein related in sequence to the cystatin family of thiol protease inhibitors. J Biol Chem 1995;270:431–436. [CrossRef]
  23. Jersmann HP, Dransfield I, Hart SP. Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages. Clin Sci 2003;105:273–278. [CrossRef]
  24. Ma P, Feng YC. Decreased serum fetuin-A levels and active inflammatory bowel disease. Am J Med Sci 2014;348:47–51. [CrossRef]
  25. Underhill DM, Ozinsky A, Smith KD, Aderem A. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci U S A 1999;96:14459–14463. [CrossRef]
  26. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14:329–342. [CrossRef]
  27. Alex P, Zachos NC, Nguyen T, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 2009;15:341–352. [CrossRef]
  28. Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 2009;58:1629–1636. [CrossRef]
  29. Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 2002;97:2820–2828. [CrossRef]